Brock E. Harper, MD
Assistant Professor, Division of Rheumatology
Brock E. Harper, MD
Division of Rheumatology
Department of Internal Medicine
University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-1165
Dr. Brock Harper is an assistant professor of Internal Medicine and Rheumatology at UTMB. He joined the UTMB faculty in July of 2010 after finishing his fellowship in Rheumatology at University of Texas Health Science Center at Houston. Prior to his fellowship training, he completed medical school at UTMB followed by residency in Internal Medicine at the Medical University of South Carolina in Charleston, S.C.
Dr. Harper is active clinically seeing patients with general rheumatologic diseases including rheumatoid arthritis, gout, systemic lupus erythematosus, scleroderma, ankylosing spondylitis as well as osteoarthritis and osteoporosis. Additionally, Dr. Harper is involved in medical education and research in scleroderma.
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Orderset
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medicaitons
- Parenteral Opioids
- Sepsis, Adult ICU
- 111 - Stroke Alert
- 112 - Stroke Activation
- 300086 - Stroke Floor Admission
- 3000000001 - Stroke Critical care without tPA
- 300088 Stroke - Transfer from Critical care to floor
- 3004002 - Stroke Discharge
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.